Michael L Roark

US Patent:

52524582, Oct 12, 1993

Filed:

Oct 16, 1992

Appl. No.:

7/963505

Inventors:

Avraham Liav - Denver CO
James F. Maher - Broken Arrow OK
Craig D. Shimasaki - Tulsa OK
C. Worth Clinkscales - Tulsa OK
Michael D. Roark - Owasso OK

Assignee:

Symex Corp. - Broken Arrow OK

International Classification:

C12Q 134
C12Q 170
C12N 926
G01N 2103
G01N 2175

US Classification:

435 5

Abstract:

A rapid and direct assay for detecting of a virus having a characteristic enzyme in clinical samples in which (1) the clinical sample is contacted in solution with a substrate for the enzyme which includes a chromogen that is cleaved from the substrate by the enzyme and a precipitating agent that reacts with the liberated chromogen to form a precipitate (2) filtering the solution to concentrate the precipitate and (3) visually observing the concentrated precipitate for the characteristic color of the chromogen.

US Patent:

57668418, Jun 16, 1998

Filed:

Jun 7, 1995

Appl. No.:

8/479789

Inventors:

Avraham Liav - Denver CO
Craig D. Shimasaki - Tulsa OK
James F. Maher - Broken Arrow OK
C. Worth Clinkscales - Tulsa OK
Michael D. Roark - Owasso OK

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK

International Classification:

C12Q 170

US Classification:

435 5

Abstract:

A kit for visually detecting the presence of a virus in a direct clinical specimen is provided. The kit employs a rapid and direct assay for visually detecting a virus having a characteristic enzyme in a direct clinical sample without the need for any culturing step, This assay contains the following steps: (1) the clinical sample is contacted in solution with a substrate for the enzyme which includes a chromogen that is cleaved from the substrate by the enzyme and a precipitating agent which reacts with the liberated chromogen to form a precipitate, (2) the precipitate is concentrated, and (3) the concentrated precipitate is visually observed for the characteristic color of the chromogen. The observance of the characteristic color confirms the presence of the virus in the clinical specimen. The kit contains (a) a buffer solution for extraction of the characteristic enzyme from the clinical sample; (b) a substrate for the characteristic enzyme, where the substrate contains a chromogen that is liberated by reaction between the characteristic enzyme and the substrate, if the characteristic enzyme is present in the clinical sample; (c) a precipitating agent which reacts with the liberated chromogen in the buffer solution to produce a colored precipitate if the characteristic enzyme is present in the clinical sample; and (d) a device for concentrating the colored precipitate sufficiently to provide a distinct, visibly detectable spot of the colored precipitate if the characteristic enzyme is present in the clinical sample.